Controlled-release carvedilol.
Carter
Natalie J
NJ
Wolters Kluwer Health | Adis, Mairangi Bay, North Shore, Auckland, New Zealand. demail@adis.co.nz
Keating
Gillian M
GM
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002227:Carbazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000077261:Carvedilol; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D009203:Myocardial Infarction / Q000150:complications; D011412:Propanolamines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000503:physiopathology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D003692:Delayed-Action Preparations; D011412:Propanolamines; D000077261:Carvedilol